The Usefulness of Positron Emission Tomography in Nonsmall Cell Lung Carcinoma;Utilidad de la Tomografía de Emisión de Positrones en el Carcinoma de Pulmón no Microcítico

Archivos de Bronconeumologia

Volumn 40, Issue 3, 2004, Pages 103-105

  Resino, M C ^a   Maldonado, A ^a   Garcia L ^a  

^a Instituto Tecnologico PET   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BRONCHOSCOPY; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EDITORIAL; ENDOSCOPIC ECHOGRAPHY; HUMAN; LUNG NON SMALL CELL CANCER; MEDIASTINOSCOPY; POSITRON EMISSION TOMOGRAPHY; THORACOSCOPY; THORACOTOMY;

EID: 1842424172     PISSN: 03002896     EISSN: None     Source Type: Journal    
DOI: 10.1157/13057888     Document Type: Editorial

References (34)

1. García Girón C, Fernández Pérez Y, Salinas Hernández P, Jara Álvarez MA. Cáncer de pulmón II. En: González Barón M, Ordóñez A, Feliú J, Zamora P, Espinosa E, De Castro J, editores. Oncología clínica. Patología especial. Madrid: McGraw-Hill-Interamericana, 1998; p. 57-80.
2. McLoud TC, Bourgouin PM, Greenberg RW. Bronchogenic carcinoma: analysis of staging in the mediastinun with CT by correlative lymph-node mapping and sampling. Radiology 1992;182:319-23.
3. Dillemans B, Deneffe G, Verschakelen M, Decramer M. Value of computed tomography and mediastinoscopy in preoperative evaluation of mediastinal nodes in non-small cell lung cancer. Eur J Cardiothorac Surg 1994;8:37-42.
4. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of PET with FDG in evaluation of small (< 1 cm), intermediate (1 to 3 cm) and larg (> 3 cm) lymph node lesions. Chest 2000;117:773-8.
5. Dahlbom M, Hoffman EJ, Hoh CK, Schipers C, Rosenqvist G, Hawkins RA, et al. Whole-body positron emission tomography: part I. Methods and preformance characteristics. J Nucl Med 1992; 33:1191-9.
6. Hagge RJ, Wong TZ, Coleman RE. Positron emission tomography: brain tumors and lung cancer. Radiol Clin North Am 2001;39:871-81.
7. Croft DR, Trapp J, Kernstine K, Kirchner P, Mullan B, Galvin J, et al. FDG-PET imaging and the diagnosis of non-small cell lung cancer in a region of high histoplasmosis prevalence. Lung Cancer 2002;36:297-301.
8. Ortiz Mera J, Pereira Vega A, Ayerbe García R, Gravalos Guzmán J, Maldonado Pérez J. A man with lung cancer and tuberculosis: a false positive by positron emission tomography and its clinical repercussions. Arch Bronconeumol 2002;38:90-2.
9. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002;32:293-321.
10. Khandani AH, Keller SM, Blaufox MD. 18Fluorodeoxyglucose positron emission tomography: false-positive lung scan. Semin Nucl Med 2002;32:212-3.
11. Kubota K, Matsuzawa T, Fujiwara T, Ito M, Hatazawa J, Iwata R, el al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990;31:1927-32.
12. Chin R Jr, Ward R, Keyes JW, Choplin RH, Reed JC, Wallenhaupt S, et al. Mediastinal staging of non-small cell lung cancer with PET. Am J Respir Crit Care Med 1995;152:2090-6.
13. Valk PE, Pounds TR, Hopkins DM, Haseman MK, Hofer GA, Greiss HB, et al. Staging non-small cell lung cancer by whole-body positron emission tomography imaging. Ann Thorac Surg 1995;60:1573-82.
14. Sazon DA, Santiago SM, Soo Hoo GW, Khonsary A, Brown C, Mandelkern M, et al. FDG-PET in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417-21.
15. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plasmann L, Reske SN. Lymph node staging in non small cell lung cancer: evaluation by FDG-PET. Thorax 1997;52:438-41.
16. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verschakelen JA, Nackaerts KL, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer: a prospective analysis of 50 cases. Leuven Lung cancer Group. Chest 1997;112:1480-6.
17. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Bogaert J, Maes A, et al. Lymph node staging in non small cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998;16:2142-9.
18. Saunders CA, Dussek JE, O'Doherty MJ, Maisey MN. Evaluation of FDG whole body PET imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-7.
19. Berlangieri SU, Scott AM, Knight SR, Fitt GJ, Hennessy OF, Tochon-Danguy HJ, et al. FDG-PET in non-invasive staging of non-small cell lung cancer. Eur Cardiothorac Surg 1999;16 (Suppl 1): 25-30.
20. Marom EM, McAdams HP, Erasmus JJ, Goodman PC, Culhane DK, Coleman RE, et al. Staging non-small cell lung cancer with whole body PET. Radiology 1999;212:803-9.
21. Bury T, Rigo P. Contribution of PET for the manegement of lung cancer. Rev Pneumol Clin 2000;56:125-31.
22. Farrell MA, McAdams HP, Herndon JE, Patz EF. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology 2000;215:886-90.
23. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastina staging in the 1990s-meta-analytic comparasion of PET and CT. Radiology 1999; 213:530-6.
24. Pieterman RM, Van Putten JW, Meuzelaar JJ, Mooyart EL, Vaalburg W, Koeter GH, et al. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med 2000;343:254-61.
25. Fritscher-Ravens A, Bohuslavizki KH, Brandt L, Bobrowski C, Lund C, Knöfel WT, et al. Mediastinal lymph node involvement in potentially resectable lung cancer. Comparison of CT, positron emission tomography and endoscopic ultrasonography with and without fine-needle aspiration. Chest 2003;123:442-51.
26. Kernstine KH, Mclaughlin KA, Menda Y, Rossi NP, Kahn DJ, Bushnell DL, et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg 2002;73:394-402.
27. Jeong HJ, Min JJ, Park JM, Chung JK, Kim BT, Jeong JM, et al. Determination of the prognostic value of [18F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002;23:865-70.
28. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002;38:261-6.
29. Wang T, Sun Y, Zhou N, et al. Fluorine-18 fluorodeoxyglucose uptake in patients with primary lung cancer. Zhonghua Wai Ke Za Zhi 2002;40:437-40.
30. Marom EM, Sarvis S, Herndon JE, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology 2002;223:453-9.
31. Pandit N, Gonen M, Krug L, Larson AM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer Eur J Nucl Med 2003;30:78-84.
32. Pugsley JM, Schmidt RA, Vesselle H. The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer J 2002;8:222-33.
33. Scott WJ, Shepherd J, Gambhir SS. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998;66:1876-85.
34. Weng E, Tran L, Rege S, Safa A, Sadeghi A, Juillard G, et al. Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially respectable lung cancer. Am J Clin Oncol 2000;23:47-52.